膀胱癌中FHIT基因异常和3号染色体微卫星杂合性缺失及相关蛋白表达的研究
|
摘要
膀胱肿瘤(tumor of bladder)是我国泌尿生殖系统最常见的肿瘤,高发年龄为50~70岁。男:女为4:1。随着我国人口老年化,膀胱肿瘤的发病也呈逐年增高的趋势,严重威胁人们的生命和健康。膀胱肿瘤95%以上为上皮性肿瘤,其中绝大多数(90%)为移行细胞癌(TCC),其次为鳞状细胞癌占2~3%,腺癌占2~3%。非上皮性肿瘤极少见,多数为肉瘤如横纹肌肉瘤。膀胱癌具有多发性、易复发的特点。近1/3的膀胱癌为多发性肿瘤。
膀胱肿瘤病因很多,一般认为与以下危险因素相关:1.长期接触一些致癌物质,如染料、纺织、皮革、橡胶、油漆等。2.吸烟是最常见的致癌因素。3.膀胱癌与长期膀胱慢性感染和异物刺激有关。4.长期服用镇痛药非那西丁可能为膀胱癌的病因或诱因。膀胱癌的确切病因并不清楚。随着分子生物学技术的快速发展及对膀胱癌分子遗传学的深入研究,为膀胱癌早期诊断和生物学治疗提供了一个全新的发展方向。
3号染色体短臂是多种肿瘤杂合性丢失和细胞遗传学异常的高发区域,3号染色体短臂上等位基因缺失是膀胱癌最常见的遗传物质改变之一。膀胱癌3号染色体短臂发生杂合性缺失(loss of heterozygosity,LOH)的频率很高,该区域早在1979年就被认为存在t(3:8)易断处。此后的研究发现,3p14.2区域有脆性位点FRA3B。3号染色体短臂上与肿瘤发生、发展密切相关的抑癌基因FHIT、hMLH及VHL分别定位于3p14-cen、3p21-22、3p25-26这三个区段之中。
脆性组氨酸三联体(fragile histindine triad,FHIT)基因是1996年Ohta等用外显子捕获法(exon trapping)确定并克隆出来的人类基因。FHIT存在于大多数正常组织中。研究发现,FHIT基因在人类多种恶性肿瘤及多种恶性肿瘤细胞系中呈现高频率的杂合缺失或甲基化。肿瘤中很少见到FHIT基因点突变的报道。因此,FHIT基因被拟定为抑癌基因。定位于染色体3p14-12区域,具有10个外显子。
FHIT基因的功能主要有四个方面:1.FHIT基因功能与其Ap3A水解酶活性有很大的关系,FHIT基因失活导致Ap3A水解酶活性的丧失,从而导致Ap3A或类似复合物水平的升高,刺激DNA聚合酶A合成DNA,通过细胞周期G1期控制点使细胞生长进入S期。2. FHIT基因功能与微管蛋白有关,发现FHIT蛋白和微管蛋白有较强的结合力,而微管蛋白对细胞的分化和增值有作用,有可能FHIT蛋白抑制肿瘤生长也同微管蛋白有关。3. FHIT基因与细胞周期控制和细胞凋亡有关。FHIT基因激活外源性caspases(凋亡蛋白酶)路径,首先激活启动子caspase8,同时,FHIT基因还激活线粒体凋亡途径,使线粒体失去跨膜电位而凋亡。4.FHIT基因与细胞对于外界环境的应激能力有关,FHIT基因失活可能会引起癌变,另外FHIT蛋白具有去除mRNA帽类似体的作用,FHIT蛋白能作用于mRNA帽类似物,影响重要基因mRNA的翻译。
目前FHIT基因的分子作用机制仍然不清楚,以下有几种学说来解释FHIT基因抑制肿瘤的机理:1.蛋白激酶C抑制剂(protein kinase C inhibitor,PKCI)假说。认为FHIT蛋白可能是PKCI,当细胞内Ca2+浓度升高达到一定水平时,PKC即被激活,并使相应的底物磷酸化而发挥一系列的生理功能,其中包括细胞内信号的传递、核基因的转录、细胞增殖和凋亡等。2. AP3A水解酶-细胞增殖调节假说。认为FHIT蛋白可能也是一种Ap3A水解酶,FHIT蛋白可以通过水解APnA来抑制细胞增殖。3.ApnA-FHIT聚合物-细胞凋亡传导信号假说。FHIT蛋白与APnA结合形成FHIT-AP3A复合蛋白,与ADP、ATP结合形成ApnP,后者与FHIT蛋白结合发生构像改变而活化,其产物又通过多种途径诱导细胞凋亡。前两个假说已被后来的研究否定,目前认为FHIT蛋白主要通过与AP3A形成复合物,通过细胞凋亡途径发挥作用。
Survivin基因是近年来发现的凋亡蛋白抑制因子(IAP)家族中的一个新成员。1997年,Altieri首先发现了survivin基因。它定位于17q25,全长14.7kb,含有3个内显子和4个外显子,编码含有142个氨基酸分子量为16.5KD的胞浆蛋白。它是近年来发现的一个调节细胞性程序死亡的蛋白质家族(IAPs)8个成员之一,Survivin是至今发现作用最强的凋亡抑制蛋白之一。
尿液中肿瘤脱落细胞能反映膀胱癌的遗传学特性。而尿液检测是一种简便、无创性的手段。通过尿液检测来早期诊断膀胱癌并监测膀胱癌术后复发的方法很多,如尿脱落细胞细胞学检查、流式细胞学检测、尿液游离膀胱肿瘤标志物检测、尿液中肿瘤相关抗原检测、检测端粒酶活性检测等。但敏感性和特异性各家报道差异性较大。
微卫星DNA(microsatellite DNA)又称短串联重复序列,微卫星DNA是广泛分布于原核、真核生物基因组中的短小串联重复的DNA序列,约占人类基因组的5%,由于许多微卫星都与基因紧密连锁甚至位于基因内部,因此微卫星的缺失常表示其连锁基因的缺失。肿瘤中微卫星异常主要表现为微卫星不稳定性(MSI)和微卫星的杂合性缺失。微卫星异常在多种肿瘤组织中可检测到,微卫星异常可作为肿瘤的分子标志应用于临床辅助诊断。
基于以上背景,本研究检测49例膀胱TCC组织及10例正常膀胱组织中FHIT基因中4个外显子的缺失、突变和甲基化情况,FHIT蛋白和Survivin蛋白表达,以及组织和尿液中FHIT基因的两个微卫星位点D3S1234和D3S1300、VHL基因连锁的微卫星位点D3S1038、hMLH1基因连锁微卫星位点D3S1561杂合性缺失情况,结合临床资料,旨在:评价FHIT基因改变与膀胱TCC发生的关系及临床意义,分析FHIT蛋白和Survivin蛋白表达在膀胱TCC发生中的临床意义和相互关系,从分子水平探讨膀胱TCC的发病机制,分析组织和尿液中FHIT基因、VHL基因、hMLH1基因微卫星位点杂合性缺失,为膀胱TCC的基因诊断提供实验依据。
本实验采用
1.聚合酶链反应-单链构象多态性分析法(PCR-SSCP)-银染法分析膀胱TCC组织中FHIT基因外显子3、4、5、8缺失和突变情况。
2.甲基化特异性PCR(MSP)方法分析膀胱TCC组织中FHIT基因CpG岛甲基化状况甲基化情况。
3.用免疫组织化学(S-P)法检测膀胱TCC组织中FHIT基因和Survivin基因蛋白表达。
4.聚合酶链反应-变性聚丙烯酰胺凝胶电泳(PCR-PAGE)-银染法分析膀胱TCC组织和尿液中FHIT基因、VHL基因、hMLH1基因微卫星位点杂合性缺失。
结果
1.49例膀胱TCC组织中21例存在一个或多个FHIT基因外显子杂合性缺失,缺失率为42.9%(21/49)。外显子3杂合性缺失率为8.2%(4/49),外显子4杂合性缺失率为10.2%(5/49),外显子5杂合性缺失率为32.7%(16/49),外显子8杂合性缺失率为0%(0/49)。一例同时出现外显子3、4、5杂合性缺失,2例同时出现外显子4、5杂合性缺失。FH1T基因4个外显子均未发现迁移率的改变即点突变。FHIT基因基因甲基化为16.3%(8/49),正常膀胱组织中无FHIT基因杂合性缺失、点突变和甲基化。
2.49例膀胱TCC中,FHIT蛋白阳性表达率为46.9% (23/49)。FHIT蛋白表达随病理分级升高而下降,与膀胱TCC病理分级间存在相关关系,FHIT蛋白阳性表达随临床分期升高而下降;Survivin蛋白阳性表达率为57.1% (28/49),Survivin蛋白表达随病理分级升高而上升,与膀胱TCC病理分级间存在相关关系。Survivin蛋白阳性表达随肿瘤临床分期升高而增高,与膀胱TCC临床分期间存在相关关系;FHIT蛋白与Survivin蛋白表达间呈负相关关系。
3.FHIT基因外显子两个微卫星位点D3S1300、D3S1234在膀胱TCC组织和尿液中的杂合性缺失率分别为50%(17/34),40%(12/30)和47.1%(16/34),40%(12/30)。与hMLH1基因连锁的微卫星位点D3S1561在膀胱TCC组织和尿液中的杂合性缺失率为40%(8/20)。与VHL基因连锁的微卫星位点D3S1038在膀胱TCC组织和尿液中的杂合性缺失率分别为35.5%(11/31)和32.3%(10/31);FHIT,hMLH1及VHL基因上述微卫星位点的杂合性缺失之间无相关关系;通过尿液FHIT,hMLH1及VHL基因微卫星位点的杂合性缺失诊断膀胱TCC的敏感性为75.5%(37/49),特异性为100%。常规尿脱落细胞学检查阳性率16.3%(8/49)。
结论
1.膀胱TCC中存在FHIT基因的杂合性缺失和甲基化,而未检测到点突变。杂合性缺失是FHIT基因主要的失活机制,杂合性缺失以外显子5为主,其次是外显子4和外显子3,未发现外显子8杂合性缺失。
2.膀胱TCC中存在FHIT蛋白异常表达,FHIT蛋白异常表达与膀胱TCC恶性程度有关。可能成为一重要的肿瘤抑制蛋白,在膀胱TCC的发生和演化中起着重要的作用。FHIT蛋白检测可作为膀胱TCC诊断指标。Survivin蛋白是膀胱TCC高表达蛋白,与膀胱TCC恶性程度和进展有关,Survivin基因是膀胱TCC发生的晚期分子事件。Survivin蛋白检测可作为膀胱TCC诊断指标。FHIT蛋白和Survivin蛋白在膀胱TCC呈负相关,表明FHIT蛋白可能通过细胞凋亡途径发挥作用。
3.3号染色体短臂上FHIT基因,hMLH1基因及VHL基因在膀胱TCC中存在高频杂合性缺失。但在膀胱TCC发生、发展中没有直接内在联系,可能是膀胱TCC发生、发展中的独立分子事件。
4.尿液中3号染色体短臂上FHIT基因,hMLH1基因及VHL基因微卫星位点杂合性缺失的联合检测可作为膀胱TCC诊断的一种特异性和敏感性较高的生物学方法。
The bladder tumor, the most common cancer of urogenital system in China, affects males four times as frequently as females, and most commonly occurs in adults between the age of 50 and 70. The incidence of bladder tumor worldwide has been increasing with population senescence year after year, Threating people's life and health seriously. 95% of the bladder tumor is the epidermis tumor. The transitional cell carcinoma(TCC) accounts for 90%. Others are squamous cell carcinoma, accounting for2-3% and adenocarcinoma, accounting for 2-3%.The non-epidermis tumor has been rarely found. It shows high recurrence rate and multiple characteristic.nearly 1/3 of bladder tumors show multiple.
A number of risky factors has been evalutated: (1) Contacting with some carcinogens for a long time, such as dye, spinning and weaving, leather, rubber, paint and so on; (2) smoking; (3) urinary bladder chronic infection and stimulation concern;(4) long time intake of analgesics,like phenacetin.But little is known about the etiology of bladder tumor. With the rapid development of molecular biology technology and molecular genitics deep study for tumor, early diagnosis and biology therapy to bladder tumor has became possible.
Loss of heterozygosity (LOH) and genetics abnormality have frequently been detected at the region of 3 chromosome short arms for many tumors.LOH for bladder tumor shows a frequent molecular event here. Research in 1979 showed that t(3:8) breakpoint was located at 3p, then FRA3B was found to be located at 3p too.There are three tumor suppressor gene,FHIT,hMLH and VHL being located separately at 3p14-cen, 3p21-22 and 3p25-26 region.
FHIT (fragile histindine triad) gene, a human gene that has been cloned by Ohta in exon trapping in 1996, located at 3p14-cen, is composed of ten exons. Abnormality of FHIT gene, as common LOH and methylation, rarely mutation ,was detected at many tumors and tumor cell lines.The function of FHIT product is associated with the following aspects:(1) AP3A hydrolase activity.(2) microtubule protein.(3) cell cycle control and apoptosis.(4) stress ability for extemal environment.Up to now, tumorigenesis mechanism of FHIT gene still is not clear. There are three hypothesises to explain it as follows: (1) PKCI (protein kinase C inhibitor) hypothesis.(2) AP3A hydrolase-cell proliferaton and ragulation hypothesis.(3) ApnA-FHIT polymers-apotosis hypothesis.
Survivin gene, one of 8 inhibitor of apoptosis proteins (IAPs), cloned by Altieri in 1997, is located at 17q25, is composed of three introns and four exons with 142 coding nucleotides, Survivin protein is one of the most power founction in IAPs.
The exfoliated urothelial cells can reflect genetic character of the bladder TCC. Urine detection is a simple and nonwound means. There are many urine detection methods to be used to diagnoze the bladder TCC, cancer-associated antigen, telomerase activity, plasma tumor marker,flow cytometric,and so on. But the specificity and sensitivity reported are various.
Microsatellite(MA) DNA, short tandem repeat sequences, 5% in human genome,are found in all prokaryotic and eukaryotic genomes. Abnormality of microsatellite, performance as MSI and LOH, can be detected in many kinds of tumors.It can be used as tumor marker in clinical diagnosis for tumor.
Method
1. LOH and mutation of exon3,4,5,8 linked with FHIT gene were detected with PCR-SSCP stain method in tissue DNA from 10 cases of the normal urinary bladder tissues and 49 cases of the bladder.
2.Ethylation of FHIT gene was detected by Methy-specific PCR in 10 cases of the normal urinary bladder tissues and 49 cases of the bladder TCC tissues.
3. The expressions of FHIT gene and survivin gene were studied by S-P immunohistochemisty in 10 cases of the normal urinary bladder tissues and 49 cases of the bladder TCC tissues.
4. Four microsatellite markers:D3S1234,D3S1300 linked with FHIT gene,D3S1561 linkedwith hMLH1 gene and D3S1038 linked with VHL gene were detected with PCR-PAGE stain method in both the urine segment DNA and tumor tissue DNA from 10 cases of the normal urinary bladder and 49 cases of the bladder TCC.
Results
1. 21 cases out of 49 caces of bladder TCC tissues have one or more LOH of exons in FHIT gene, The LOH frequencies of exons detected in the bladder TCC tissues from the 49 cases were 42.9% (21/49), LOH of exon 3 was 8.2% (4/49), LOH of exon 4 was10.2% (5/49), LOH of exon 5 was 32.7% (16/49), LOH of exon 8 was 0(0/49). There was not mutation of FHIT gene in the bladder TCC .The frequency of methylation detected in the bladder TCC tissues from the 49 cases was 16.3% (8/49). There were not LOH ,mutation and methylation in the normal bladder tissues.
2. All the normal urinary bladder tissues showed positive staining pattern of FHIT protein, negative staining pattern of survivin protein. Positive rate of FHIT protein in 49 cases of the bladder TCC tissues is 46.9%(23/49). The difference of positive rate between Grade I and Grade II、III cases was significant. The difference of positive rate between Tis~T1 cases and T2~T4 cases showed a trend of decreasing, but there was no statistically significant difference; Positive rate of survivin in 49 cases of the bladder TCC tissues is 57.1%(28/49). The difference of positive rate between Grade I and GradeII、III cases was significant, the difference of positive rate between Tis~T1 cases and T2~T4 cases was significant, too. The expression of FHIT protein was reversely correlated to survivin protein.
3. LOH frequency of D3S1234,D3S1300 that was linked with FHIT gene was found In informative 49 cases as 50%(17/34), 40%(12/30) in tissue and 47.1%(16/34), 40%(12/30) in urine segment, respectively. LOH frequency of D3S1561 that was linked with hMLH1 gene was found in informative 49 cases as 40%(8/20) in tissue and urine segment. LOH frequency of D3S1038 that was linked with VHL gene was found In informative 49 cases as 35.5%(11/31) in tissue, 32.3%(10/31) in urine segment, respectively. The LOH of D3S1234,D3S1300 were not correlated to the LOH of D3S1561 and D3S1038. The sensitivity and the specifity of the way using LOH of MS in urine segment for detection of bladder TCC were 75.5% (37/49) and 100%, positive rate of regular urine cytology is 16.3(8/49).
Conclusion
1. Here were frequent LOH and methylation of FHIT gene in bladder TCC. LOH was mainly alteration of FHIT gene.The LOH was mainly found at exon 5. There was not LOH of exon 8.
2. FHIT protein and survivin protein may play an important role in bladder TCC. FHIT and Survivin gene may be a late molecular even to the bladder TCC. Expression of FHIT protein and survivin protein may be used as prognostic marker for the bladder TCC. Expression of FHIT protein correlated significantly to survivin protein. FHIT protein may suppress the development of the bladder TCC by the way of apoptosis.
3. There were high frequent LOH of MS at FHIT gene, VHL gene and hMLH1 gene in the bladder TCC. LOH of MS in FHIT gene, VHL gene and hMLH1 gene may be independent events in the bladder TCC. The analysis of LOH of the MS linked with FHIT gene, hMLH1 gene and VHL gene in urine segment was a sensitive and specific tool in detection of bladder TCC.
膀胱肿瘤病因很多,一般认为与以下危险因素相关:1.长期接触一些致癌物质,如染料、纺织、皮革、橡胶、油漆等。2.吸烟是最常见的致癌因素。3.膀胱癌与长期膀胱慢性感染和异物刺激有关。4.长期服用镇痛药非那西丁可能为膀胱癌的病因或诱因。膀胱癌的确切病因并不清楚。随着分子生物学技术的快速发展及对膀胱癌分子遗传学的深入研究,为膀胱癌早期诊断和生物学治疗提供了一个全新的发展方向。
3号染色体短臂是多种肿瘤杂合性丢失和细胞遗传学异常的高发区域,3号染色体短臂上等位基因缺失是膀胱癌最常见的遗传物质改变之一。膀胱癌3号染色体短臂发生杂合性缺失(loss of heterozygosity,LOH)的频率很高,该区域早在1979年就被认为存在t(3:8)易断处。此后的研究发现,3p14.2区域有脆性位点FRA3B。3号染色体短臂上与肿瘤发生、发展密切相关的抑癌基因FHIT、hMLH及VHL分别定位于3p14-cen、3p21-22、3p25-26这三个区段之中。
脆性组氨酸三联体(fragile histindine triad,FHIT)基因是1996年Ohta等用外显子捕获法(exon trapping)确定并克隆出来的人类基因。FHIT存在于大多数正常组织中。研究发现,FHIT基因在人类多种恶性肿瘤及多种恶性肿瘤细胞系中呈现高频率的杂合缺失或甲基化。肿瘤中很少见到FHIT基因点突变的报道。因此,FHIT基因被拟定为抑癌基因。定位于染色体3p14-12区域,具有10个外显子。
FHIT基因的功能主要有四个方面:1.FHIT基因功能与其Ap3A水解酶活性有很大的关系,FHIT基因失活导致Ap3A水解酶活性的丧失,从而导致Ap3A或类似复合物水平的升高,刺激DNA聚合酶A合成DNA,通过细胞周期G1期控制点使细胞生长进入S期。2. FHIT基因功能与微管蛋白有关,发现FHIT蛋白和微管蛋白有较强的结合力,而微管蛋白对细胞的分化和增值有作用,有可能FHIT蛋白抑制肿瘤生长也同微管蛋白有关。3. FHIT基因与细胞周期控制和细胞凋亡有关。FHIT基因激活外源性caspases(凋亡蛋白酶)路径,首先激活启动子caspase8,同时,FHIT基因还激活线粒体凋亡途径,使线粒体失去跨膜电位而凋亡。4.FHIT基因与细胞对于外界环境的应激能力有关,FHIT基因失活可能会引起癌变,另外FHIT蛋白具有去除mRNA帽类似体的作用,FHIT蛋白能作用于mRNA帽类似物,影响重要基因mRNA的翻译。
目前FHIT基因的分子作用机制仍然不清楚,以下有几种学说来解释FHIT基因抑制肿瘤的机理:1.蛋白激酶C抑制剂(protein kinase C inhibitor,PKCI)假说。认为FHIT蛋白可能是PKCI,当细胞内Ca2+浓度升高达到一定水平时,PKC即被激活,并使相应的底物磷酸化而发挥一系列的生理功能,其中包括细胞内信号的传递、核基因的转录、细胞增殖和凋亡等。2. AP3A水解酶-细胞增殖调节假说。认为FHIT蛋白可能也是一种Ap3A水解酶,FHIT蛋白可以通过水解APnA来抑制细胞增殖。3.ApnA-FHIT聚合物-细胞凋亡传导信号假说。FHIT蛋白与APnA结合形成FHIT-AP3A复合蛋白,与ADP、ATP结合形成ApnP,后者与FHIT蛋白结合发生构像改变而活化,其产物又通过多种途径诱导细胞凋亡。前两个假说已被后来的研究否定,目前认为FHIT蛋白主要通过与AP3A形成复合物,通过细胞凋亡途径发挥作用。
Survivin基因是近年来发现的凋亡蛋白抑制因子(IAP)家族中的一个新成员。1997年,Altieri首先发现了survivin基因。它定位于17q25,全长14.7kb,含有3个内显子和4个外显子,编码含有142个氨基酸分子量为16.5KD的胞浆蛋白。它是近年来发现的一个调节细胞性程序死亡的蛋白质家族(IAPs)8个成员之一,Survivin是至今发现作用最强的凋亡抑制蛋白之一。
尿液中肿瘤脱落细胞能反映膀胱癌的遗传学特性。而尿液检测是一种简便、无创性的手段。通过尿液检测来早期诊断膀胱癌并监测膀胱癌术后复发的方法很多,如尿脱落细胞细胞学检查、流式细胞学检测、尿液游离膀胱肿瘤标志物检测、尿液中肿瘤相关抗原检测、检测端粒酶活性检测等。但敏感性和特异性各家报道差异性较大。
微卫星DNA(microsatellite DNA)又称短串联重复序列,微卫星DNA是广泛分布于原核、真核生物基因组中的短小串联重复的DNA序列,约占人类基因组的5%,由于许多微卫星都与基因紧密连锁甚至位于基因内部,因此微卫星的缺失常表示其连锁基因的缺失。肿瘤中微卫星异常主要表现为微卫星不稳定性(MSI)和微卫星的杂合性缺失。微卫星异常在多种肿瘤组织中可检测到,微卫星异常可作为肿瘤的分子标志应用于临床辅助诊断。
基于以上背景,本研究检测49例膀胱TCC组织及10例正常膀胱组织中FHIT基因中4个外显子的缺失、突变和甲基化情况,FHIT蛋白和Survivin蛋白表达,以及组织和尿液中FHIT基因的两个微卫星位点D3S1234和D3S1300、VHL基因连锁的微卫星位点D3S1038、hMLH1基因连锁微卫星位点D3S1561杂合性缺失情况,结合临床资料,旨在:评价FHIT基因改变与膀胱TCC发生的关系及临床意义,分析FHIT蛋白和Survivin蛋白表达在膀胱TCC发生中的临床意义和相互关系,从分子水平探讨膀胱TCC的发病机制,分析组织和尿液中FHIT基因、VHL基因、hMLH1基因微卫星位点杂合性缺失,为膀胱TCC的基因诊断提供实验依据。
本实验采用
1.聚合酶链反应-单链构象多态性分析法(PCR-SSCP)-银染法分析膀胱TCC组织中FHIT基因外显子3、4、5、8缺失和突变情况。
2.甲基化特异性PCR(MSP)方法分析膀胱TCC组织中FHIT基因CpG岛甲基化状况甲基化情况。
3.用免疫组织化学(S-P)法检测膀胱TCC组织中FHIT基因和Survivin基因蛋白表达。
4.聚合酶链反应-变性聚丙烯酰胺凝胶电泳(PCR-PAGE)-银染法分析膀胱TCC组织和尿液中FHIT基因、VHL基因、hMLH1基因微卫星位点杂合性缺失。
结果
1.49例膀胱TCC组织中21例存在一个或多个FHIT基因外显子杂合性缺失,缺失率为42.9%(21/49)。外显子3杂合性缺失率为8.2%(4/49),外显子4杂合性缺失率为10.2%(5/49),外显子5杂合性缺失率为32.7%(16/49),外显子8杂合性缺失率为0%(0/49)。一例同时出现外显子3、4、5杂合性缺失,2例同时出现外显子4、5杂合性缺失。FH1T基因4个外显子均未发现迁移率的改变即点突变。FHIT基因基因甲基化为16.3%(8/49),正常膀胱组织中无FHIT基因杂合性缺失、点突变和甲基化。
2.49例膀胱TCC中,FHIT蛋白阳性表达率为46.9% (23/49)。FHIT蛋白表达随病理分级升高而下降,与膀胱TCC病理分级间存在相关关系,FHIT蛋白阳性表达随临床分期升高而下降;Survivin蛋白阳性表达率为57.1% (28/49),Survivin蛋白表达随病理分级升高而上升,与膀胱TCC病理分级间存在相关关系。Survivin蛋白阳性表达随肿瘤临床分期升高而增高,与膀胱TCC临床分期间存在相关关系;FHIT蛋白与Survivin蛋白表达间呈负相关关系。
3.FHIT基因外显子两个微卫星位点D3S1300、D3S1234在膀胱TCC组织和尿液中的杂合性缺失率分别为50%(17/34),40%(12/30)和47.1%(16/34),40%(12/30)。与hMLH1基因连锁的微卫星位点D3S1561在膀胱TCC组织和尿液中的杂合性缺失率为40%(8/20)。与VHL基因连锁的微卫星位点D3S1038在膀胱TCC组织和尿液中的杂合性缺失率分别为35.5%(11/31)和32.3%(10/31);FHIT,hMLH1及VHL基因上述微卫星位点的杂合性缺失之间无相关关系;通过尿液FHIT,hMLH1及VHL基因微卫星位点的杂合性缺失诊断膀胱TCC的敏感性为75.5%(37/49),特异性为100%。常规尿脱落细胞学检查阳性率16.3%(8/49)。
结论
1.膀胱TCC中存在FHIT基因的杂合性缺失和甲基化,而未检测到点突变。杂合性缺失是FHIT基因主要的失活机制,杂合性缺失以外显子5为主,其次是外显子4和外显子3,未发现外显子8杂合性缺失。
2.膀胱TCC中存在FHIT蛋白异常表达,FHIT蛋白异常表达与膀胱TCC恶性程度有关。可能成为一重要的肿瘤抑制蛋白,在膀胱TCC的发生和演化中起着重要的作用。FHIT蛋白检测可作为膀胱TCC诊断指标。Survivin蛋白是膀胱TCC高表达蛋白,与膀胱TCC恶性程度和进展有关,Survivin基因是膀胱TCC发生的晚期分子事件。Survivin蛋白检测可作为膀胱TCC诊断指标。FHIT蛋白和Survivin蛋白在膀胱TCC呈负相关,表明FHIT蛋白可能通过细胞凋亡途径发挥作用。
3.3号染色体短臂上FHIT基因,hMLH1基因及VHL基因在膀胱TCC中存在高频杂合性缺失。但在膀胱TCC发生、发展中没有直接内在联系,可能是膀胱TCC发生、发展中的独立分子事件。
4.尿液中3号染色体短臂上FHIT基因,hMLH1基因及VHL基因微卫星位点杂合性缺失的联合检测可作为膀胱TCC诊断的一种特异性和敏感性较高的生物学方法。
The bladder tumor, the most common cancer of urogenital system in China, affects males four times as frequently as females, and most commonly occurs in adults between the age of 50 and 70. The incidence of bladder tumor worldwide has been increasing with population senescence year after year, Threating people's life and health seriously. 95% of the bladder tumor is the epidermis tumor. The transitional cell carcinoma(TCC) accounts for 90%. Others are squamous cell carcinoma, accounting for2-3% and adenocarcinoma, accounting for 2-3%.The non-epidermis tumor has been rarely found. It shows high recurrence rate and multiple characteristic.nearly 1/3 of bladder tumors show multiple.
A number of risky factors has been evalutated: (1) Contacting with some carcinogens for a long time, such as dye, spinning and weaving, leather, rubber, paint and so on; (2) smoking; (3) urinary bladder chronic infection and stimulation concern;(4) long time intake of analgesics,like phenacetin.But little is known about the etiology of bladder tumor. With the rapid development of molecular biology technology and molecular genitics deep study for tumor, early diagnosis and biology therapy to bladder tumor has became possible.
Loss of heterozygosity (LOH) and genetics abnormality have frequently been detected at the region of 3 chromosome short arms for many tumors.LOH for bladder tumor shows a frequent molecular event here. Research in 1979 showed that t(3:8) breakpoint was located at 3p, then FRA3B was found to be located at 3p too.There are three tumor suppressor gene,FHIT,hMLH and VHL being located separately at 3p14-cen, 3p21-22 and 3p25-26 region.
FHIT (fragile histindine triad) gene, a human gene that has been cloned by Ohta in exon trapping in 1996, located at 3p14-cen, is composed of ten exons. Abnormality of FHIT gene, as common LOH and methylation, rarely mutation ,was detected at many tumors and tumor cell lines.The function of FHIT product is associated with the following aspects:(1) AP3A hydrolase activity.(2) microtubule protein.(3) cell cycle control and apoptosis.(4) stress ability for extemal environment.Up to now, tumorigenesis mechanism of FHIT gene still is not clear. There are three hypothesises to explain it as follows: (1) PKCI (protein kinase C inhibitor) hypothesis.(2) AP3A hydrolase-cell proliferaton and ragulation hypothesis.(3) ApnA-FHIT polymers-apotosis hypothesis.
Survivin gene, one of 8 inhibitor of apoptosis proteins (IAPs), cloned by Altieri in 1997, is located at 17q25, is composed of three introns and four exons with 142 coding nucleotides, Survivin protein is one of the most power founction in IAPs.
The exfoliated urothelial cells can reflect genetic character of the bladder TCC. Urine detection is a simple and nonwound means. There are many urine detection methods to be used to diagnoze the bladder TCC, cancer-associated antigen, telomerase activity, plasma tumor marker,flow cytometric,and so on. But the specificity and sensitivity reported are various.
Microsatellite(MA) DNA, short tandem repeat sequences, 5% in human genome,are found in all prokaryotic and eukaryotic genomes. Abnormality of microsatellite, performance as MSI and LOH, can be detected in many kinds of tumors.It can be used as tumor marker in clinical diagnosis for tumor.
Method
1. LOH and mutation of exon3,4,5,8 linked with FHIT gene were detected with PCR-SSCP stain method in tissue DNA from 10 cases of the normal urinary bladder tissues and 49 cases of the bladder.
2.Ethylation of FHIT gene was detected by Methy-specific PCR in 10 cases of the normal urinary bladder tissues and 49 cases of the bladder TCC tissues.
3. The expressions of FHIT gene and survivin gene were studied by S-P immunohistochemisty in 10 cases of the normal urinary bladder tissues and 49 cases of the bladder TCC tissues.
4. Four microsatellite markers:D3S1234,D3S1300 linked with FHIT gene,D3S1561 linkedwith hMLH1 gene and D3S1038 linked with VHL gene were detected with PCR-PAGE stain method in both the urine segment DNA and tumor tissue DNA from 10 cases of the normal urinary bladder and 49 cases of the bladder TCC.
Results
1. 21 cases out of 49 caces of bladder TCC tissues have one or more LOH of exons in FHIT gene, The LOH frequencies of exons detected in the bladder TCC tissues from the 49 cases were 42.9% (21/49), LOH of exon 3 was 8.2% (4/49), LOH of exon 4 was10.2% (5/49), LOH of exon 5 was 32.7% (16/49), LOH of exon 8 was 0(0/49). There was not mutation of FHIT gene in the bladder TCC .The frequency of methylation detected in the bladder TCC tissues from the 49 cases was 16.3% (8/49). There were not LOH ,mutation and methylation in the normal bladder tissues.
2. All the normal urinary bladder tissues showed positive staining pattern of FHIT protein, negative staining pattern of survivin protein. Positive rate of FHIT protein in 49 cases of the bladder TCC tissues is 46.9%(23/49). The difference of positive rate between Grade I and Grade II、III cases was significant. The difference of positive rate between Tis~T1 cases and T2~T4 cases showed a trend of decreasing, but there was no statistically significant difference; Positive rate of survivin in 49 cases of the bladder TCC tissues is 57.1%(28/49). The difference of positive rate between Grade I and GradeII、III cases was significant, the difference of positive rate between Tis~T1 cases and T2~T4 cases was significant, too. The expression of FHIT protein was reversely correlated to survivin protein.
3. LOH frequency of D3S1234,D3S1300 that was linked with FHIT gene was found In informative 49 cases as 50%(17/34), 40%(12/30) in tissue and 47.1%(16/34), 40%(12/30) in urine segment, respectively. LOH frequency of D3S1561 that was linked with hMLH1 gene was found in informative 49 cases as 40%(8/20) in tissue and urine segment. LOH frequency of D3S1038 that was linked with VHL gene was found In informative 49 cases as 35.5%(11/31) in tissue, 32.3%(10/31) in urine segment, respectively. The LOH of D3S1234,D3S1300 were not correlated to the LOH of D3S1561 and D3S1038. The sensitivity and the specifity of the way using LOH of MS in urine segment for detection of bladder TCC were 75.5% (37/49) and 100%, positive rate of regular urine cytology is 16.3(8/49).
Conclusion
1. Here were frequent LOH and methylation of FHIT gene in bladder TCC. LOH was mainly alteration of FHIT gene.The LOH was mainly found at exon 5. There was not LOH of exon 8.
2. FHIT protein and survivin protein may play an important role in bladder TCC. FHIT and Survivin gene may be a late molecular even to the bladder TCC. Expression of FHIT protein and survivin protein may be used as prognostic marker for the bladder TCC. Expression of FHIT protein correlated significantly to survivin protein. FHIT protein may suppress the development of the bladder TCC by the way of apoptosis.
3. There were high frequent LOH of MS at FHIT gene, VHL gene and hMLH1 gene in the bladder TCC. LOH of MS in FHIT gene, VHL gene and hMLH1 gene may be independent events in the bladder TCC. The analysis of LOH of the MS linked with FHIT gene, hMLH1 gene and VHL gene in urine segment was a sensitive and specific tool in detection of bladder TCC.
引文
1. Varinderpal S Dhillon, Mohd Shahid and Syed Akhtar Husain. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin, Molecular Cancer 2004,3:33 doi:10.1186/1476-4598-3-33.
2. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands[J]. Proc Natl Acid Sci USA,1996, 93 (18):9821-9826.
3. Ohta M,Inoue H,Cotticelli MG,et al.FHIT gene spanning the chromosome 3p14.2 fragile-site and renal carcinoma-assosiated t(3;8) breakpoint is abnormal in digestivetract cancer Cell,1996,84:587-597.
4. PaceHC,GarrisonPN,RlbjnsonAK,etal.Genetic,biochemical,andcrystallographiccharacterization of FHIT-substrate complexes as the active signaling form of FHIT.Proc NatlAcad Sci USA,1998,95 (10):5484-5489.
5. Chaudhuri AR,Khan IA,Prasad V,et al.The tumor suppressor protein FHIT.a novel interaction with tubuline.J biol Chem,1999,274 (34):24378-24382.
6. Dumon KR,Ishii H,Vecchione A,et al.Fragile histidine traid expression delays tumor development and induces apoptosis in human pancreatic ccancer.Cancer Res, 2001, 61(12):4827~4836.
7. Roz L,Gramegna M,Ishii H,et al.Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumor igenicity in lung and cervical cancer cell lines.Proc Natl Acad Sci USA,2002,99(6):3615-3620.
8. Gemma A,Hagiwara K,Ke Y,et al.FHIT mutations in human primary gastric cancer. Cancer Res,1997,57(8):1435-7.
9.周清华,陈军,覃扬,等.人非小细胞肺癌中FHIT等位基因缺失和突变的研究[J].中国肺癌杂志,2001,4(1):12-14.
10.李立,安倩,冯晓莉等.肺癌组织3号染色体短臂上抑癌基因异常改变的初步分析[J].中华医学杂志,2001,81(7):399-401.
11. Stein CK,Glover TW,Palme JL,et al.Direct correlation between FRA3B expression and cigarette smoking.Genes Chromosomes Cancer,2002,34:333-340.
12.王允,周清华,刘伦旭等.肺癌FHIT基因表达下降的临床病理生理意义及与肿瘤细胞增殖、凋亡的关系研究[J].中华医学遗传学杂志,2001,18:178-182.
13. Luceri C,Guglielmi F,DeFilippo C,et al.Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas.Scand J Gastroenterol,2000,35:637- 641.
14. Huiping C,Kristjansdottir S,Bergthorsson JT,et al.High frequency of LOH,MSI and abnormal expression of FHIT in gastric cancer.Eur J Cancer,2002,38(5):728-35.
15. Louhelainen J,Wijkstrom H,Hemminki K,et al.Multiple regions with allelic loss at chromosome3 in superficial multifocal bladder tumors.Int J Oncol,2001,18(1):201-10.
16. Skopelitou AS,Gloustianou G,Bai M,etal.FHITgene expression in human urinary bladder transitional cell carcinomas.In Vivo,2001,15(2):169~73.
17.孙立峰,周青,汪渊.抑癌基因FHIT第8和第5外显子在原发性肝癌中纯合性缺失与点突变的研究[J].Journal of Practical Oncology2002,17(5):308-310.
18. Jaenisch R,Bird A.Epigenetic regulation of gene expression how the genome integrates intrinsic and environmental signals [J].Nature Genet,2003,33:245-254.
19. Bird A.DNA methylation patterns and epigenetic memory[J]. Genes Dev,2002,16:6-21.
20. Fuks F,Hurd PJ,Wolf D.The methyl CpG binding protein MeC links DNA methylation to histone methylatin [J].Jbilo Chem, 2003,278:4035-40.
21. Zochbauer-Muller S,Fong KM,Maitra A,et al.5cCpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.Cancer Res,2001,61:3581-3585.
22. Yang Q,Nakamura M,Nakamura Y,et al.Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.Clin Cancer Res, 2002, 8:2890-2893.
23. Takagi S,koyama S.Guided eruption of an impacted second premolar associated with a dentigerou scyst in the maxillary sinus of a6-year-old child.Joral Maxill of acSurg, 1998,56:237-239.
24. Virmani AK,Muller C,Rathi A,et al.Aberant methylation during cervical carcinogenesis [J]. Clin Cancer Res,2001,7(3):584.
25. Maruyama R,Toyooka KO,et al.Aberrant promoter methylation profile of bladdercancer and its relationship to clinicopathological feature[J].Cancer Res, 2001, 61 (24): 8659.
26.戴观荣,张玉新,邓鉴文,赵为国等.胃癌中FHIT基因异常甲基化及其与临床病理学的关系[J].广东医学杂志.2006,27(4):496-498.
27. Turki T,Trapasso F,Yendamuri S.et al.Allele loss and prmoter hypermethylation of VHL ,RAR-beta,RASSF1A,and FHIT tumor.suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.Cancer RES,2003,63(13):3724-3728.
28. Yang Q,Mori I,Shan L,et al.Biallelic mactivation of ratinoic acid recepter beta-2 gene by epigenitc change in breast cancer.Am Jpathol,2001,158(1):299-303.
29. Duan XM,Zhang JY,Wu JS,et al.Abnormal expression of FHIT gene in human primary gastrointestinal cancers.Hunan Yi Ke Da Xue Xue Bao.2000,25(4):331-333.
30.王兴元,孙燕,李卫东等.肺癌组织频繁出现FHIT基因转录本的缺失[J].中华结核和呼吸杂志,1999,22(3):159-162.
31. Guo Z,Johansson SL,Rhim JS,et al.Fragile histidine triad gene expression in primary prostate cancer and in an invitro model. Prostate,2000, 43(2),101~110.
32.王莉,董陆佳,田方等.白血病中FHIT基因的异常表达和缺失[J].中国实验血液学杂志,2003,11(2):153-160.
33.肖泽均,张建军,郑闪等.膀胱移行细胞癌3号染色体短臂上抑癌基因杂合性缺失的研究[J].中华医学杂志,2002,82(20):1375-1377.
34.曾友俊,候宁,赵坡.膀胱癌脆性组氨酸三体FHIT蛋白表达缺失及其意义[J].诊断病理学杂志,2004,11(2):105-107.
35.何崇生,黄剑飞,陈莉.脆性组氨酸三联体基因(FHIT)在膀胱移行细胞肿瘤中的表达及其临床意义[J].苏州大学学报(医学版),2006,26(2):265-267.
1. Sard L,Accomero P,Tornielle S,et al.The tumor-suppressor gene FHIT is invived in the regulation of apoptosis in cell cycle control.Proc Natl Acad Sci USA, 1999, 96(15): 8489-8492.
2. Hao XP,Willis GE,Pretlow TG,et al.Loss of Fragile histidine triad eexpression in colorectal carcinomas and premalignent lesion.Cancer Res,2000,60:18-21.
3.曾友俊,候宁,赵坡.膀胱癌脆性组氨酸三体FHIT蛋白表达缺失及其意义[J].诊断病理学杂志,2004,11(2):105-107.
4. Pearson JD,DeWald DB,Mathews WR,et al.Amino acid sequence and characterization of a protein inhibitor of protein kinase C.J biol Chem,1990,265(8):4583-4591.
5. McDonald JR,Walsh MP.Ca2+-binding proteins from bovine brain including a potentinhibitor of protein kinase C. Biochem J,1985,232 (2):B559-567.
6. Brzoska PM,Chen H,ZhuY,et al.The product of the ataxia telangiectasia group D complementing gene,ATDC,interacts with a protein kinase C substrate and inhibitor. Proc Natl Acad Sci USA,1995,92(17):7824-7828.
7. Huebner K,Garrison PN, Barnes LD, et al.The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet,1997,32(1):7-31.
8. Fraser ED,Walsh MP.The major endogenous bovine brain protein kinase C inhibitor is a heat-labile protein.FEBS Lett,1991,294(3):285-289.
9. Lima CD,Klein MG,Weinstein IB,et al.Three-dimensional structure of human protein kinase C interacting protein1,amember of the HIT family of proteins.Proc Natl Acad Sci USA,1996, 93(11): 5357-5362.
10. Varshavsky A.Diadenosine5,,5,,,,0/-P1,P4 tetraphosphate:a pleiotropically acting alarmone? Cell,1983,34(3):711-712.
11. Barnes LD,Garrison PN,Siprashvili Z,et alFHIT,a putative tumor suppressor in humans, is a dinucleoside 5,,5,,,,0/-P1,P3-triphosphate hydrolase. Biochemistry, 1996,35(36):11529-11535.
12. Siprashvili Z,Sozzi G,Barnes LD,et al.Replacement of FHIT in cancer cells suppresses tumorigenicity.Proc Natl Acad Sci USA, 1997,94(25):13771-13776.
13. Lima CD,D’Amico KL,Naday I,et al.MAD analysis of FHIT a putative human tumor suppressor from the HIT protein family. Structure,1997,5(6):763-774.
14. Brenner C.FHIT-substrate complexes a new paradigm in reversible protein phosphorylation. Phosphorous,Sulfur,andSilicon,1998,144-146:746-752.
15. Holcik M.The IAP proteins.Trendsin Genetics, 2002, 18(10): 537~8.
16. Suzuki A,Ito T,Kawano H,et al.Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell ddeath. Oncogene, 2000,19,1346~53.
17. T,Shiraki K,Sugimoto K,et al.Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology, 2000, 31,1080~5.
18. Takai N,Miyazaki T,Nishida M,et al.Survivin expression correlates with clinical stage,
19. histological grade,invasive behavior and survival rate in endometrial carcinoma. Cancer Lett,2002,184,105~16.
20. Papapetropoulos A,Fulton D,Mahboubi K,et al.Angiopoietin 1 inhibits endothelial cell apoptosis via the Akt/survivin pathway.J Bio Chem,2000,275:9102-9105.
21. O’.Connor DS,Schhechner JS,Adida C,et al.Control of apoptosis during angiogenesis by survivin express in endothelial cell.Am J Pathol , 2000,156:393-398.
22. Hunt A,Evan G.Apoptosis.Till death us dopart [J]. Science, 2001, 293(5536): 1748-1785.
23. Mirza A,McGuirk M,Hockenberry TN,et al.Human survivin is negatively regulated by wild-type p53 and participate in p53 dependent apoptotic pathway. Oncogene, 2002,21, 2613~22.
24. Tanaka K,Iwamoto S,Gon G,et al.Expression of survivin and its relationship to loss of apoptosis in breast carcinoma.Clin Cancer Res, 2000,6, 127~34.
25. Swana HS,Grossman D,Anthony JN,et al.Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.N Engl J Med,1999,341:452-453.
26. Smith SD,Wheeler MA,Plescia J,et al.Urine detection of survivin and diagnosis of bladder cancer.JAMA,2001,285(3):324~8.
27.宋涛,李鸣,石怀银等.凋亡抑制基因存活素在膀胱癌中的表达及意义[J].中华泌尿外科杂志,2004,25(12):848-850.
28.赵坡,宋欣,宁元元等.肝细胞癌脆性组氨酸三联体FHIT蛋白表达丢失研究[J].中华肝胆外科杂志,2004,10(1):52-54.
29.杨万广,王钟富,谷元廷. FHIT和Survivin在乳腺癌进展过程中的表达和意义. Journal of basic and clinical oncology, 2006, 1939: 194-198.
30.肖泽均,张建军,郑闪等.膀胱移行细胞癌3号染色体短臂上抑癌基因杂合性缺失的研究[J].中华医学杂志,2002,82(20):1375-1377.
31. Guo Z,Johansson SL,Rhim JS,et al.Fragile histidine triad gene expression in primary prostate cancer and in an invitro model.Prostate,2000, 43(2),101~110.
32.王莉,董陆佳,田方等.白血病中FHIT基因的异常表达和缺失[J].中国实验血液学杂志,2003,11(2):153-160.
33.何崇生,黄剑飞,陈莉.脆性组氨酸三联体基因(FHIT)在膀胱移行细胞肿瘤中的表达及其临床意义[J].苏州大学学报(医学版),2006,26(2):265-267.
34.蔡清萍,李海倩,付志仁等.三联脆组基因对胰腺癌细胞增殖及凋亡的影响[J].中华消化杂志,2001,21(7):423-425.
35.孔梅,陈慰浙,陈智等.源性FHIT基因表达对胃癌细胞株MGC-803凋亡作用的影响[J].浙江大学学报(医学版),2004,33(4):133-137.
1 Fradet Y.Molecular and immunological approaches in the management of bladder cancer. Urol Clin North Am, 1991,18(3):515-524.
2 Sheinfeild J,Reuter VE,Melamed MR,et al.Enhanced bladder cancer detection with the lewis X antigen as a marker of neoplastic transformation. J Urol, 1990,143:285-288.
3 Tanaka K,Hakashi M,Miyake K,et al.Immunocytochemically demonstrated expression of epithelial membrane antigen and carcinoem bryonic antigen by exfoliated urinary cell in patients with bladder cancer. Urol Int, 1994, 52(3):140-144.
4 Longin A,Fontaniere B,et al.A useful monoclonal antibody (BL2-10D10) to indentify tumor cells in urine cytology. Cancer. 1990,65(6):1412-1417.
5 Mao L,Sohoenberg MP,Scicchitano M,et al.Molecular detection of primary bladder cancer by microsatellite analysis.Science,1996,271:659-662.
6 Zhang J,Fan Z,GaoY,et al.Detecting bladder cancer in the Chinese by microsatellite analysis:ethnic and etiological considerations[J]. Natl Cancer Inst,2001,93:45-50.
7肖玉平,韩埩波,李锦毅等.胃癌基因杂合性缺失及微卫星不稳定性的研究[J].中国医科大学学报,2006,25(2):122-124.
8白福鼎,史时芳.膀胱癌组织及尿脱落细胞CD44v6表达的研究.中华泌尿外科杂志, 1999;20(2):101.
9 Vanderpoel HG,Vanbalken MR,Schamhart DHJ,et al.Blladder wash cytology quantitative cytology and quantitative BTA test in patients with superficial bladder cancer.Urology,1998,51:44-50.
10潘柏年,韩可汉,曹毓林等.尿脱落细胞核形态学测量及临床意义[J].中华泌尿外科杂志,1996,17:375-376.
11 Steinberg GD,Trump DL,Cummings KB.Metastic bladder nutural history clinical course and consideration for treatment.Urol Clin North Am,1992,19:735-746.
12 Schambeck CM,Stieber P,Schmeller N,et al.CYFRA21-1 quantity measurement in the urine of patients with carcinoma of urinary bladder and tract.Anticancer Res,1997,17: 3063-3065.
13 LokeshwarVB,YoungM,WeiD,et al.HA-Haase test:a test for detecting bladder cancerand monitoring tumor recurrence.Jurol,1998,159:241,923.
14 Wiener HG,Mian CH,Haitel A,et al.Can urine bound diagnostic tests replace cystoscop in the management of bladder cancer.J Uro1 ,1998,159:1876-1880.
15 Bianco FJ,Gervasi DC,Tiguert R,et al.Matrix metalloproteinase 9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.Clin Cancer Res,1998,4:3011-3016.
16 Leyh H,Treiber U,Thomas L,et al.Results of a earopean multicenter trial comparing the BTATRAKtest to urine cytology in patient suspected of having bladder cancer.J Urol,1998,159:244,934.
17 Golijanin D,Sherman Y,Shapiro A,et al.Detection of bladder tumors by immunostaining of the LewisX antigen in cells from voided urine.Urology,1995,46:173-177.
18 Kavaler E,Landman J,ChangY,et al.Detecting human bladder carcinoma cells in voided urine samples by assaying for the presenc of telomerase activity.Cancer,1998,82:7082- 714.
19 .Linn JF,Lango M,Halachmi S,et al.Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients.Int J Cancer,1997,60:625- 629.
20 Arzimanoglou II,Gilbert F,Barber HR. Micsatellite instability in human solid tumors.Cancer,1998,82(10):1808-1820.
21 Sasatomi E,Finkelstein SD,Woods JD,et al.Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stageII no-small cell lung carcinoma:implications for the timing of lymph node metastasis and prognostic value[J].Cancer Res,2002,62(9):2681-2689.
22 Li M,Zhang ZF,Reuter VE,et al.Chromosome 3 allelic losses and microsatellite alterantions in transitional cell carcinoma of the urinary bladder.Am J Pathol 1996,149: 229-235.
23 Vieten L,Belair CD,Savelieva L,et al.Minimal deletion of 3p13-14.2 associated with immortalization of human uroepithelial cells.Genes Chromosom. Cancer, 1998, 21:39 -48.
24 Ohta M,Inoue H,Cotticelli MG,et al.FHIT gene spanning the chromosome 3p14.2 fragilesite and renal carcinoma-assosiated t(3;8) breakpoint is abnormal in digestivetract cancer.Cell,1996,84:587-597.
25周清华,陈军,覃扬等.人非小细胞肺癌中FHIT等位基因缺失和突变的研究[J].中国肺癌杂志,2001,4(1):12-14.
26肖泽均,张建军,郑闪等.膀胱移行细胞癌3号染色体短臂上抑癌基因杂合性缺失的研究[J].中华医学杂志,2002,82(20):1375-1377.
27 Latif F,Tory K,Gnarra J,et al.Identification of the von Hippel-Lindau disease tumor suppressor gene[J].Science (Washington DC),1993,360:1317-1320.
28 Baek MJ,Kang H,Kim SE,et al.Expression of hMLH1 is inactivated in the astric adenomas with enhanced microsatellite instability[J].Br J Cancer, 2001, 85(8): 1147 -1152.
29 Benachenhou N,Guiral S,Gorska-Flipot I,et al.Frequent loss of heterozygosity at the DNA mismatch-repairloci hMLH1 and hMSH3 in sporadic breast cancer[J].Br J Cancer,1999,79(728):1012-1017.
30成凡,楚雍烈,贺大林.尿脱落细胞6号染色体长臂的微卫星改变诊断膀胱肿瘤[J].第四军医大学学报,2003,24(8):693-695.
31扬林,贺大林,何辉.尿脱落细胞微卫星改分析在膀胱癌诊断中的应用[J].现代泌尿外科杂志,2003,8(4):193-195.
32范振斌,张建军,白瑾峰等.膀胱移行细胞癌病人癌组织与尿脱落细胞中9p微卫星不稳定性的分析[J].中华医学杂志,2000,80(1):44-45.
1 Ohta M,Inoue H,Cotticelli MG,et al.FHIT gene spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint,is abnormal in digestive tract cancers [J].Cell,1996,84:587-597.
2 Sozzi G,Pastorino U,Moiraghi L,et al.Loss of FHIT function in lung cancer and preinvasive bronchial lesions.Cancer Res,1998,58:5032-5037.
3 Campiglio M,Pekarsky Y,Menard S,et al.FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease.Cancer Res, 1999, 59: 3866 -3869.
4 Kisielewski AE,Xiao GH,Liu SC,et al.Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.Oncogene,1998,17:83-91.
5 Sorio C,Baron A,Orlandini S,et al.The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.Cancer Res,1999,59:1308-1314.
6 Xiao GH,Jin F,Klein-Szanto AJP,et al.The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down-regulated in kidney cancers.Am J Pathol,1997,151:1541-1547.
7 Birrer MJ,Hendrics D,Farley J,et al.Abnormal FHIT expression in malignant and premalignant lesions of the cervix.Cancer Res,1999,59:5270-5274.
8 Thiagalingam S,Lisitsyn NA,Hamaguchi M,et al.Evaluation of the FHIT gene in colorectal cancers.Cancer Res,1996,56:2936-2939.
9 Shridhar R,Shridhar V,Wang X,et al.Frequent breakpoints in the 3p14.2 fragile site,FRA 3B,in pancreatic tumors.Cancer Res,1996,56:4347-4350.
10 Iwai T,Yokota S ,Nakao M,et al.Frequent aberration of FHIT gene expression in acute leukemias.Cancer Res,1998,58∶5 182-5187
11 Tanaka H,Shimada Y,Haradad H,et al.Methylation of the 5′CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cellcarcinomas.Cancer Res,1998,58:3429-3434.
12 Barnes LD,Garrison PN,Siprashvili Z,et al.FHIT,a putative tumor suppressor in humans,is a dinucleoside 5′,5-P1,P3-triphosphatehy drolase. Biochemistry, 1996, 35:11529-11535.
13 Kisselev LL,Justesen J,Wolfson AD,et al.Diadenosine oligophosphates (Ap(n)A),a novel class of signalling molecules? FEBS Lett,1998,427:157-163.
14 Roz I,Gramegna M,Ishii H,et al.Restoration off ragile histidine triad(FHIT)expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer celllines [J].Proc Natl Acad Sci USA,2002,99(6):3615-3620.
15 Becker NA,Thorland EC,Denison SR,et al. Evidence that in stability with in the FRA3B region extends four megabases [J].Oncogene,2002,21(57):8713-8722.
16 Pearson JD,DeWald DB,Mathews WR,et al.Amino acid sequence and characterization of a protein inhibitor of protein kinase C.J Biol Chem,1990, 265 (8):4583-4591.
17 McDonald JR,Walsh MP.Ca2+-binding proteins from bovine brain including a potent inhibitor of protein kinase C.Biochem J,1985,232(2):559-567.
18 Brzoska PM,Chen H,Zhu Y,et al.The product of the ataxia-telangiectasia group D complementing gene,ATDC,interacts with a protein kinase C substrate and inhibitor. Proc Natl Acad Sci USA,1995,92(17):7824-7828.
19 Huebner K,Garrison PN,Barnes LD,et al.The role of the FHIT/FRA3B locus in cancer.Annu Rev Genet,1997,32(1):7-31.
20 Klein MG,Yao Y,Slosberg ED,et al.Characterization of PKCI and comparative studies with FHIT,related members of the HIT protein family.Exp Cell Res, 1998, 244(1): 26-32.
21 Fraser ED,Walsh MP.The major endogenous bovine brain protein kinase C inhibitor is a heat-labile protein.FEBS Lett,1991,294(3):285-289.
22 Lima CD,Klein MG,Weinstein IB,et al.Three-dimensional structure of human protein kinase C interacting protein1,a member of the HIT family of proteins.Proc Natl AcadSci USA,1996,93(11):5357-5362.
23 Varshavsky A.Diadenosine5、,5-P1,P4-tetraphosphate:a pleiotropically acting alarmone Cell,1983,34(3):711-712.
24 Barnes LD,Garrison PN,Siprashvili Z,et al. FHIT,a putative tumor suppressor in humans,is a dinucleoside5、,5…-P1,P3-triphosphate hydrolase. Biochemistry, 1996, 35(36):11529-11535.
25 Siprashvili Z,Sozzi G,Barnes LD,et al.Replacement of FHIT in cancer cells suppresses tumorigenicity.Proc Natl Acad Sci USA,1997,94(25):13771-13776.
26 Sard L,Accornero P,Tornielli S,et al.The tumor suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control.Proc Natl Acad Sci USA, 1999, 96(15): 8489-8492.
27 Ji L,Fang B,Yen N,et al.Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.Cancer Res,1999,59(14)B3333-3339.
28 Lima CD,D.Amico KL,Naday I,et al.MAD analysis of FHIT,a putative human tumor suppressor from the HIT protein family.Structure,1997,5(6):763-774.
29 Brenner C.FHIT-substrate complexes:a new paradigm in reversible protein phosphoryla-tion. Phosphorous,Sulfur,and Silicon,1998,144-146:746-752.
30 Brenner C,Bieganowski P,Pace HC,et al.The histidine triad superfamily of nucleotidebind-ing proteins.J Cell Physiol,1999,181(2):179-187.
31 Kuroki T,Trapasso F,Yendamuri S,et, al.Allele loss and promoter hypermethylation of VHL,RAR,beta,RASSFIA,and FHIT tumor suppressor genes on chromosome 3p in esophageal squanmous cell carcinoma.Cancer Res,2003,63(13):3724-3728.
32 [Maruyama R,Toyooka KO,et,al.Aberrant promoter methylation profile of bladdercancer and its relationship to clinicopthological features J].Cancer Res,2001,61 (24):8659.
33 Zochbauer Muller S,Fong KM,Maitra A,et,al.5CPG island methylation of the FHITgene is correlated with loss of gene expression in lung and breast cancer.Cancer Res,2001,61(9):3581-3585.
34 Wada T,Louhelainen J,Hemminki K,et al.The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction [J].BJU Int,2001,87:876-881.
35 Raffaele B,leconardG,Gomella,et al.Loss of FHIT expression intransitional cell carcinoma of the urinary bladder [J].Am J Pathol,2000,156:419-424.
36何崇生,黄剑飞,陈莉.脆性组胺酸三聚体基因(FHIT)在膀胱移行细胞肿瘤的表达及其临床意义[J].苏州大学学报,2006,26(2):265-266
1 Holcik M.The IAP proteins[J].Trends in genetics,2002,18(10):537-538.
2 Ambrosini G,Adida C,Altieri DC. A novel anti-apoptosis gene,surviving, expressed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921.
3 Chantalat L,Skoufias DA,Kleman JP,et al.Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions[J].Mol Cell,2000,6(1): 183-189.
4 O' Connor DS,Grossman D,Plescia J, et al.Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin[J]. Proc Natl Acad Sci USA, 2000, 97(24):13103- 13107.
5 Tamm I,Wang Y,Sausville E,et al.IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bas,caspase,and anticancer drugs[J].Cancer Res,1998,58(23): 5315-5320.
6 Sela B.Survivin:Anti-apoptosis protein and a prognosticmarker for tumor progression and recurrence[J].Harefuah, 2002,141(1):103-107.
7 Lehner R,Lucia MS,Jarboe EA,et al.Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma[J].Appl Immunohistochem MolMorphol, 2002,10 (2):134-138.
8 Mahotka C,Wenzel M,Springer E,et al.Survivin-delta Ex3 and surviving-2B:two novel splice variants of the apoptosis inhibitor surviving with different antiapoptotic properties[J].Cancer Res,1999,59(24):6097-6102.
9 Krieg A,Mahotka C,Krieg T, et al.Expression of different survivin variants in gastric carcinomas: first clues to a role of surviving-2B in tumour progression[J].BrJ Cancer,2002,86(5):737-743.
10 Vegran F,Boidot R,Oudin C,et al.Distinct expression of surviving splice variants in breast carcinomas[J].Int J Oncol,2005,27(4):1151-1157.
11 Zheng W,Ma X,Wei D,et al.Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells[J].DNA Seq, 2005, 16(5):321-328.
12 Dohi T,Okada K,Xia F,et al.An IAP-IAP complex inhibits apoptosis[J].J Biol Chem 2004; 279(33): 34087-34090.
13 Tamm I, Wang Y, Sausville E,et al.IAP-family protein surviving inhibits caspases, and anticancer drugs[J].Cancer Res,1998,58: 5315-5320.
14 Verhagen AM,Ekort PG,Pakusch M,et al.Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins[J]. Cell,2000, 102(1):43-53.
15 Mitza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-depend apoptotic pathway[J].Oncogene, 2002,21(17):2613-2622.
16 Fortugno P,Wall NR,Giodini A,et al.Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function[J].J Cell Sci,2002,115 (3):575-585.
17 Takai N,Miyazaki T,Nishida M,et al.Survivin expression correlates with clinical stage, histologicalgrade, invasive behaviorand survival rate in endometrial carcinoma[J]. Cancer Lett,2002,184(1):105-106.
18 Thompson CB.Apoptosis in the pathogenesis and treatment of disease [J]. Science, 1995, 267 (5203):1456-1462.
19 Smith SD, Wheeler MA, Plescia, et al.Urine detection ofSurvivin and diagnosis ofbladder cancer[J]. JAMA, 2001, 285(3): 324-328.
20 Sharp JD,HausladenDA,MaherM G,et al.Bladder cancerdetection with urinary survivin, an Inhibitor ofapoptosis[J].FrontBiosci,2002,7: 36-41.
21 Shariat SF,Casella R,Khoddami SM,et al.Urine survivin detection is a sensitivemarker for the noninvasive diagnosis of bladder cancer[J].J Urol, 2004, 171(2 pt1):626-630.
22 Ku JH,Kwak C,Lee HS,et al.Expression of survivin, a noval inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder[J].J Urol, 2004,171(2 pt1): 631-635.
23 Hausladen DA,Wheeler MA,Altieri DC,et al.Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome[J].J uro,2003,170(1):230-234.
24 Xing Z,Conway EM.Essential role of surviving,an inhibitor of apoptosis protein, in T cell development ,maturation, and homeostasis [J].J Exp Med,2004,199(1):69-80.
25 Hu Y,Cherton-Horvat G,Dragowska V,et al.Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo [J].Clin Cancer Res,2003,9:2826-2836.
26 Tu SP,Jiang XH,Lin MC,et al.Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer [J]. Cancer Res,2003,63:7724.7732.
27 Hague A, Eveson JW, MacFarlane M,et al.Caspase-3 expression is reduced in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage[J]. J Pathol,2004, 204:175-182.
28 Zhang XY, Zhong LH,Hu K,et al.Expression of survivin and its correlation with P53 in non-small cell lung cancer[J].Med J Wuhan University,2004,25(3):271-274.
29 Meng H,Lu C,Mabuchi H,et al.Prognostic significance and different properties of survivin splicing variants in gastric cancer[J].Cancer Lett,2004,216:147-155.
30 Olie RA,Simoes-Wust AP,Baumann B,et al.A novel antisense oligonucleotide targeting Surviving expression induces apoptosis and sensitizes lung cancer cells to chemotherapy [J].CancerRes,2000, 60(1): 2805-2809.
31 Kato J,Kuwaabara Y,MitaniM,et al.Expression of survivin in esophageal cancer correlation with the prognosis and response to chemotherapy[J]. Int JCancer, 2001, 95(2):92-95.
32 Mesri M,WallN R,Li J,et al.Cancer gene therapy using a surviving mutant adenovirus [J].J Clin Invest, 2001, 108(7):981-990.
33 Gazzaniga P,Gradilone A,Giuliani L,et al.Expression and prognostic significance of livin, Surviving and other apoptosis-related genes in the progression of superficialbladder cancer[J].AnnOnco,l 2003,14(1):85-90.
34 Mesri M,Morales-Ruiz M,Ackermann EJ,et al.Suppression of vascular endothelial growthfactor-mediated endothelial cell proteition by Survivin targeting[J].AmJ Pathol,2001,8(4):305-310.
2. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands[J]. Proc Natl Acid Sci USA,1996, 93 (18):9821-9826.
3. Ohta M,Inoue H,Cotticelli MG,et al.FHIT gene spanning the chromosome 3p14.2 fragile-site and renal carcinoma-assosiated t(3;8) breakpoint is abnormal in digestivetract cancer Cell,1996,84:587-597.
4. PaceHC,GarrisonPN,RlbjnsonAK,etal.Genetic,biochemical,andcrystallographiccharacterization of FHIT-substrate complexes as the active signaling form of FHIT.Proc NatlAcad Sci USA,1998,95 (10):5484-5489.
5. Chaudhuri AR,Khan IA,Prasad V,et al.The tumor suppressor protein FHIT.a novel interaction with tubuline.J biol Chem,1999,274 (34):24378-24382.
6. Dumon KR,Ishii H,Vecchione A,et al.Fragile histidine traid expression delays tumor development and induces apoptosis in human pancreatic ccancer.Cancer Res, 2001, 61(12):4827~4836.
7. Roz L,Gramegna M,Ishii H,et al.Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumor igenicity in lung and cervical cancer cell lines.Proc Natl Acad Sci USA,2002,99(6):3615-3620.
8. Gemma A,Hagiwara K,Ke Y,et al.FHIT mutations in human primary gastric cancer. Cancer Res,1997,57(8):1435-7.
9.周清华,陈军,覃扬,等.人非小细胞肺癌中FHIT等位基因缺失和突变的研究[J].中国肺癌杂志,2001,4(1):12-14.
10.李立,安倩,冯晓莉等.肺癌组织3号染色体短臂上抑癌基因异常改变的初步分析[J].中华医学杂志,2001,81(7):399-401.
11. Stein CK,Glover TW,Palme JL,et al.Direct correlation between FRA3B expression and cigarette smoking.Genes Chromosomes Cancer,2002,34:333-340.
12.王允,周清华,刘伦旭等.肺癌FHIT基因表达下降的临床病理生理意义及与肿瘤细胞增殖、凋亡的关系研究[J].中华医学遗传学杂志,2001,18:178-182.
13. Luceri C,Guglielmi F,DeFilippo C,et al.Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas.Scand J Gastroenterol,2000,35:637- 641.
14. Huiping C,Kristjansdottir S,Bergthorsson JT,et al.High frequency of LOH,MSI and abnormal expression of FHIT in gastric cancer.Eur J Cancer,2002,38(5):728-35.
15. Louhelainen J,Wijkstrom H,Hemminki K,et al.Multiple regions with allelic loss at chromosome3 in superficial multifocal bladder tumors.Int J Oncol,2001,18(1):201-10.
16. Skopelitou AS,Gloustianou G,Bai M,etal.FHITgene expression in human urinary bladder transitional cell carcinomas.In Vivo,2001,15(2):169~73.
17.孙立峰,周青,汪渊.抑癌基因FHIT第8和第5外显子在原发性肝癌中纯合性缺失与点突变的研究[J].Journal of Practical Oncology2002,17(5):308-310.
18. Jaenisch R,Bird A.Epigenetic regulation of gene expression how the genome integrates intrinsic and environmental signals [J].Nature Genet,2003,33:245-254.
19. Bird A.DNA methylation patterns and epigenetic memory[J]. Genes Dev,2002,16:6-21.
20. Fuks F,Hurd PJ,Wolf D.The methyl CpG binding protein MeC links DNA methylation to histone methylatin [J].Jbilo Chem, 2003,278:4035-40.
21. Zochbauer-Muller S,Fong KM,Maitra A,et al.5cCpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.Cancer Res,2001,61:3581-3585.
22. Yang Q,Nakamura M,Nakamura Y,et al.Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.Clin Cancer Res, 2002, 8:2890-2893.
23. Takagi S,koyama S.Guided eruption of an impacted second premolar associated with a dentigerou scyst in the maxillary sinus of a6-year-old child.Joral Maxill of acSurg, 1998,56:237-239.
24. Virmani AK,Muller C,Rathi A,et al.Aberant methylation during cervical carcinogenesis [J]. Clin Cancer Res,2001,7(3):584.
25. Maruyama R,Toyooka KO,et al.Aberrant promoter methylation profile of bladdercancer and its relationship to clinicopathological feature[J].Cancer Res, 2001, 61 (24): 8659.
26.戴观荣,张玉新,邓鉴文,赵为国等.胃癌中FHIT基因异常甲基化及其与临床病理学的关系[J].广东医学杂志.2006,27(4):496-498.
27. Turki T,Trapasso F,Yendamuri S.et al.Allele loss and prmoter hypermethylation of VHL ,RAR-beta,RASSF1A,and FHIT tumor.suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.Cancer RES,2003,63(13):3724-3728.
28. Yang Q,Mori I,Shan L,et al.Biallelic mactivation of ratinoic acid recepter beta-2 gene by epigenitc change in breast cancer.Am Jpathol,2001,158(1):299-303.
29. Duan XM,Zhang JY,Wu JS,et al.Abnormal expression of FHIT gene in human primary gastrointestinal cancers.Hunan Yi Ke Da Xue Xue Bao.2000,25(4):331-333.
30.王兴元,孙燕,李卫东等.肺癌组织频繁出现FHIT基因转录本的缺失[J].中华结核和呼吸杂志,1999,22(3):159-162.
31. Guo Z,Johansson SL,Rhim JS,et al.Fragile histidine triad gene expression in primary prostate cancer and in an invitro model. Prostate,2000, 43(2),101~110.
32.王莉,董陆佳,田方等.白血病中FHIT基因的异常表达和缺失[J].中国实验血液学杂志,2003,11(2):153-160.
33.肖泽均,张建军,郑闪等.膀胱移行细胞癌3号染色体短臂上抑癌基因杂合性缺失的研究[J].中华医学杂志,2002,82(20):1375-1377.
34.曾友俊,候宁,赵坡.膀胱癌脆性组氨酸三体FHIT蛋白表达缺失及其意义[J].诊断病理学杂志,2004,11(2):105-107.
35.何崇生,黄剑飞,陈莉.脆性组氨酸三联体基因(FHIT)在膀胱移行细胞肿瘤中的表达及其临床意义[J].苏州大学学报(医学版),2006,26(2):265-267.
1. Sard L,Accomero P,Tornielle S,et al.The tumor-suppressor gene FHIT is invived in the regulation of apoptosis in cell cycle control.Proc Natl Acad Sci USA, 1999, 96(15): 8489-8492.
2. Hao XP,Willis GE,Pretlow TG,et al.Loss of Fragile histidine triad eexpression in colorectal carcinomas and premalignent lesion.Cancer Res,2000,60:18-21.
3.曾友俊,候宁,赵坡.膀胱癌脆性组氨酸三体FHIT蛋白表达缺失及其意义[J].诊断病理学杂志,2004,11(2):105-107.
4. Pearson JD,DeWald DB,Mathews WR,et al.Amino acid sequence and characterization of a protein inhibitor of protein kinase C.J biol Chem,1990,265(8):4583-4591.
5. McDonald JR,Walsh MP.Ca2+-binding proteins from bovine brain including a potentinhibitor of protein kinase C. Biochem J,1985,232 (2):B559-567.
6. Brzoska PM,Chen H,ZhuY,et al.The product of the ataxia telangiectasia group D complementing gene,ATDC,interacts with a protein kinase C substrate and inhibitor. Proc Natl Acad Sci USA,1995,92(17):7824-7828.
7. Huebner K,Garrison PN, Barnes LD, et al.The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet,1997,32(1):7-31.
8. Fraser ED,Walsh MP.The major endogenous bovine brain protein kinase C inhibitor is a heat-labile protein.FEBS Lett,1991,294(3):285-289.
9. Lima CD,Klein MG,Weinstein IB,et al.Three-dimensional structure of human protein kinase C interacting protein1,amember of the HIT family of proteins.Proc Natl Acad Sci USA,1996, 93(11): 5357-5362.
10. Varshavsky A.Diadenosine5,,5,,,,0/-P1,P4 tetraphosphate:a pleiotropically acting alarmone? Cell,1983,34(3):711-712.
11. Barnes LD,Garrison PN,Siprashvili Z,et alFHIT,a putative tumor suppressor in humans, is a dinucleoside 5,,5,,,,0/-P1,P3-triphosphate hydrolase. Biochemistry, 1996,35(36):11529-11535.
12. Siprashvili Z,Sozzi G,Barnes LD,et al.Replacement of FHIT in cancer cells suppresses tumorigenicity.Proc Natl Acad Sci USA, 1997,94(25):13771-13776.
13. Lima CD,D’Amico KL,Naday I,et al.MAD analysis of FHIT a putative human tumor suppressor from the HIT protein family. Structure,1997,5(6):763-774.
14. Brenner C.FHIT-substrate complexes a new paradigm in reversible protein phosphorylation. Phosphorous,Sulfur,andSilicon,1998,144-146:746-752.
15. Holcik M.The IAP proteins.Trendsin Genetics, 2002, 18(10): 537~8.
16. Suzuki A,Ito T,Kawano H,et al.Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell ddeath. Oncogene, 2000,19,1346~53.
17. T,Shiraki K,Sugimoto K,et al.Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology, 2000, 31,1080~5.
18. Takai N,Miyazaki T,Nishida M,et al.Survivin expression correlates with clinical stage,
19. histological grade,invasive behavior and survival rate in endometrial carcinoma. Cancer Lett,2002,184,105~16.
20. Papapetropoulos A,Fulton D,Mahboubi K,et al.Angiopoietin 1 inhibits endothelial cell apoptosis via the Akt/survivin pathway.J Bio Chem,2000,275:9102-9105.
21. O’.Connor DS,Schhechner JS,Adida C,et al.Control of apoptosis during angiogenesis by survivin express in endothelial cell.Am J Pathol , 2000,156:393-398.
22. Hunt A,Evan G.Apoptosis.Till death us dopart [J]. Science, 2001, 293(5536): 1748-1785.
23. Mirza A,McGuirk M,Hockenberry TN,et al.Human survivin is negatively regulated by wild-type p53 and participate in p53 dependent apoptotic pathway. Oncogene, 2002,21, 2613~22.
24. Tanaka K,Iwamoto S,Gon G,et al.Expression of survivin and its relationship to loss of apoptosis in breast carcinoma.Clin Cancer Res, 2000,6, 127~34.
25. Swana HS,Grossman D,Anthony JN,et al.Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.N Engl J Med,1999,341:452-453.
26. Smith SD,Wheeler MA,Plescia J,et al.Urine detection of survivin and diagnosis of bladder cancer.JAMA,2001,285(3):324~8.
27.宋涛,李鸣,石怀银等.凋亡抑制基因存活素在膀胱癌中的表达及意义[J].中华泌尿外科杂志,2004,25(12):848-850.
28.赵坡,宋欣,宁元元等.肝细胞癌脆性组氨酸三联体FHIT蛋白表达丢失研究[J].中华肝胆外科杂志,2004,10(1):52-54.
29.杨万广,王钟富,谷元廷. FHIT和Survivin在乳腺癌进展过程中的表达和意义. Journal of basic and clinical oncology, 2006, 1939: 194-198.
30.肖泽均,张建军,郑闪等.膀胱移行细胞癌3号染色体短臂上抑癌基因杂合性缺失的研究[J].中华医学杂志,2002,82(20):1375-1377.
31. Guo Z,Johansson SL,Rhim JS,et al.Fragile histidine triad gene expression in primary prostate cancer and in an invitro model.Prostate,2000, 43(2),101~110.
32.王莉,董陆佳,田方等.白血病中FHIT基因的异常表达和缺失[J].中国实验血液学杂志,2003,11(2):153-160.
33.何崇生,黄剑飞,陈莉.脆性组氨酸三联体基因(FHIT)在膀胱移行细胞肿瘤中的表达及其临床意义[J].苏州大学学报(医学版),2006,26(2):265-267.
34.蔡清萍,李海倩,付志仁等.三联脆组基因对胰腺癌细胞增殖及凋亡的影响[J].中华消化杂志,2001,21(7):423-425.
35.孔梅,陈慰浙,陈智等.源性FHIT基因表达对胃癌细胞株MGC-803凋亡作用的影响[J].浙江大学学报(医学版),2004,33(4):133-137.
1 Fradet Y.Molecular and immunological approaches in the management of bladder cancer. Urol Clin North Am, 1991,18(3):515-524.
2 Sheinfeild J,Reuter VE,Melamed MR,et al.Enhanced bladder cancer detection with the lewis X antigen as a marker of neoplastic transformation. J Urol, 1990,143:285-288.
3 Tanaka K,Hakashi M,Miyake K,et al.Immunocytochemically demonstrated expression of epithelial membrane antigen and carcinoem bryonic antigen by exfoliated urinary cell in patients with bladder cancer. Urol Int, 1994, 52(3):140-144.
4 Longin A,Fontaniere B,et al.A useful monoclonal antibody (BL2-10D10) to indentify tumor cells in urine cytology. Cancer. 1990,65(6):1412-1417.
5 Mao L,Sohoenberg MP,Scicchitano M,et al.Molecular detection of primary bladder cancer by microsatellite analysis.Science,1996,271:659-662.
6 Zhang J,Fan Z,GaoY,et al.Detecting bladder cancer in the Chinese by microsatellite analysis:ethnic and etiological considerations[J]. Natl Cancer Inst,2001,93:45-50.
7肖玉平,韩埩波,李锦毅等.胃癌基因杂合性缺失及微卫星不稳定性的研究[J].中国医科大学学报,2006,25(2):122-124.
8白福鼎,史时芳.膀胱癌组织及尿脱落细胞CD44v6表达的研究.中华泌尿外科杂志, 1999;20(2):101.
9 Vanderpoel HG,Vanbalken MR,Schamhart DHJ,et al.Blladder wash cytology quantitative cytology and quantitative BTA test in patients with superficial bladder cancer.Urology,1998,51:44-50.
10潘柏年,韩可汉,曹毓林等.尿脱落细胞核形态学测量及临床意义[J].中华泌尿外科杂志,1996,17:375-376.
11 Steinberg GD,Trump DL,Cummings KB.Metastic bladder nutural history clinical course and consideration for treatment.Urol Clin North Am,1992,19:735-746.
12 Schambeck CM,Stieber P,Schmeller N,et al.CYFRA21-1 quantity measurement in the urine of patients with carcinoma of urinary bladder and tract.Anticancer Res,1997,17: 3063-3065.
13 LokeshwarVB,YoungM,WeiD,et al.HA-Haase test:a test for detecting bladder cancerand monitoring tumor recurrence.Jurol,1998,159:241,923.
14 Wiener HG,Mian CH,Haitel A,et al.Can urine bound diagnostic tests replace cystoscop in the management of bladder cancer.J Uro1 ,1998,159:1876-1880.
15 Bianco FJ,Gervasi DC,Tiguert R,et al.Matrix metalloproteinase 9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.Clin Cancer Res,1998,4:3011-3016.
16 Leyh H,Treiber U,Thomas L,et al.Results of a earopean multicenter trial comparing the BTATRAKtest to urine cytology in patient suspected of having bladder cancer.J Urol,1998,159:244,934.
17 Golijanin D,Sherman Y,Shapiro A,et al.Detection of bladder tumors by immunostaining of the LewisX antigen in cells from voided urine.Urology,1995,46:173-177.
18 Kavaler E,Landman J,ChangY,et al.Detecting human bladder carcinoma cells in voided urine samples by assaying for the presenc of telomerase activity.Cancer,1998,82:7082- 714.
19 .Linn JF,Lango M,Halachmi S,et al.Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients.Int J Cancer,1997,60:625- 629.
20 Arzimanoglou II,Gilbert F,Barber HR. Micsatellite instability in human solid tumors.Cancer,1998,82(10):1808-1820.
21 Sasatomi E,Finkelstein SD,Woods JD,et al.Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stageII no-small cell lung carcinoma:implications for the timing of lymph node metastasis and prognostic value[J].Cancer Res,2002,62(9):2681-2689.
22 Li M,Zhang ZF,Reuter VE,et al.Chromosome 3 allelic losses and microsatellite alterantions in transitional cell carcinoma of the urinary bladder.Am J Pathol 1996,149: 229-235.
23 Vieten L,Belair CD,Savelieva L,et al.Minimal deletion of 3p13-14.2 associated with immortalization of human uroepithelial cells.Genes Chromosom. Cancer, 1998, 21:39 -48.
24 Ohta M,Inoue H,Cotticelli MG,et al.FHIT gene spanning the chromosome 3p14.2 fragilesite and renal carcinoma-assosiated t(3;8) breakpoint is abnormal in digestivetract cancer.Cell,1996,84:587-597.
25周清华,陈军,覃扬等.人非小细胞肺癌中FHIT等位基因缺失和突变的研究[J].中国肺癌杂志,2001,4(1):12-14.
26肖泽均,张建军,郑闪等.膀胱移行细胞癌3号染色体短臂上抑癌基因杂合性缺失的研究[J].中华医学杂志,2002,82(20):1375-1377.
27 Latif F,Tory K,Gnarra J,et al.Identification of the von Hippel-Lindau disease tumor suppressor gene[J].Science (Washington DC),1993,360:1317-1320.
28 Baek MJ,Kang H,Kim SE,et al.Expression of hMLH1 is inactivated in the astric adenomas with enhanced microsatellite instability[J].Br J Cancer, 2001, 85(8): 1147 -1152.
29 Benachenhou N,Guiral S,Gorska-Flipot I,et al.Frequent loss of heterozygosity at the DNA mismatch-repairloci hMLH1 and hMSH3 in sporadic breast cancer[J].Br J Cancer,1999,79(728):1012-1017.
30成凡,楚雍烈,贺大林.尿脱落细胞6号染色体长臂的微卫星改变诊断膀胱肿瘤[J].第四军医大学学报,2003,24(8):693-695.
31扬林,贺大林,何辉.尿脱落细胞微卫星改分析在膀胱癌诊断中的应用[J].现代泌尿外科杂志,2003,8(4):193-195.
32范振斌,张建军,白瑾峰等.膀胱移行细胞癌病人癌组织与尿脱落细胞中9p微卫星不稳定性的分析[J].中华医学杂志,2000,80(1):44-45.
1 Ohta M,Inoue H,Cotticelli MG,et al.FHIT gene spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint,is abnormal in digestive tract cancers [J].Cell,1996,84:587-597.
2 Sozzi G,Pastorino U,Moiraghi L,et al.Loss of FHIT function in lung cancer and preinvasive bronchial lesions.Cancer Res,1998,58:5032-5037.
3 Campiglio M,Pekarsky Y,Menard S,et al.FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease.Cancer Res, 1999, 59: 3866 -3869.
4 Kisielewski AE,Xiao GH,Liu SC,et al.Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.Oncogene,1998,17:83-91.
5 Sorio C,Baron A,Orlandini S,et al.The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.Cancer Res,1999,59:1308-1314.
6 Xiao GH,Jin F,Klein-Szanto AJP,et al.The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down-regulated in kidney cancers.Am J Pathol,1997,151:1541-1547.
7 Birrer MJ,Hendrics D,Farley J,et al.Abnormal FHIT expression in malignant and premalignant lesions of the cervix.Cancer Res,1999,59:5270-5274.
8 Thiagalingam S,Lisitsyn NA,Hamaguchi M,et al.Evaluation of the FHIT gene in colorectal cancers.Cancer Res,1996,56:2936-2939.
9 Shridhar R,Shridhar V,Wang X,et al.Frequent breakpoints in the 3p14.2 fragile site,FRA 3B,in pancreatic tumors.Cancer Res,1996,56:4347-4350.
10 Iwai T,Yokota S ,Nakao M,et al.Frequent aberration of FHIT gene expression in acute leukemias.Cancer Res,1998,58∶5 182-5187
11 Tanaka H,Shimada Y,Haradad H,et al.Methylation of the 5′CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cellcarcinomas.Cancer Res,1998,58:3429-3434.
12 Barnes LD,Garrison PN,Siprashvili Z,et al.FHIT,a putative tumor suppressor in humans,is a dinucleoside 5′,5-P1,P3-triphosphatehy drolase. Biochemistry, 1996, 35:11529-11535.
13 Kisselev LL,Justesen J,Wolfson AD,et al.Diadenosine oligophosphates (Ap(n)A),a novel class of signalling molecules? FEBS Lett,1998,427:157-163.
14 Roz I,Gramegna M,Ishii H,et al.Restoration off ragile histidine triad(FHIT)expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer celllines [J].Proc Natl Acad Sci USA,2002,99(6):3615-3620.
15 Becker NA,Thorland EC,Denison SR,et al. Evidence that in stability with in the FRA3B region extends four megabases [J].Oncogene,2002,21(57):8713-8722.
16 Pearson JD,DeWald DB,Mathews WR,et al.Amino acid sequence and characterization of a protein inhibitor of protein kinase C.J Biol Chem,1990, 265 (8):4583-4591.
17 McDonald JR,Walsh MP.Ca2+-binding proteins from bovine brain including a potent inhibitor of protein kinase C.Biochem J,1985,232(2):559-567.
18 Brzoska PM,Chen H,Zhu Y,et al.The product of the ataxia-telangiectasia group D complementing gene,ATDC,interacts with a protein kinase C substrate and inhibitor. Proc Natl Acad Sci USA,1995,92(17):7824-7828.
19 Huebner K,Garrison PN,Barnes LD,et al.The role of the FHIT/FRA3B locus in cancer.Annu Rev Genet,1997,32(1):7-31.
20 Klein MG,Yao Y,Slosberg ED,et al.Characterization of PKCI and comparative studies with FHIT,related members of the HIT protein family.Exp Cell Res, 1998, 244(1): 26-32.
21 Fraser ED,Walsh MP.The major endogenous bovine brain protein kinase C inhibitor is a heat-labile protein.FEBS Lett,1991,294(3):285-289.
22 Lima CD,Klein MG,Weinstein IB,et al.Three-dimensional structure of human protein kinase C interacting protein1,a member of the HIT family of proteins.Proc Natl AcadSci USA,1996,93(11):5357-5362.
23 Varshavsky A.Diadenosine5、,5-P1,P4-tetraphosphate:a pleiotropically acting alarmone Cell,1983,34(3):711-712.
24 Barnes LD,Garrison PN,Siprashvili Z,et al. FHIT,a putative tumor suppressor in humans,is a dinucleoside5、,5…-P1,P3-triphosphate hydrolase. Biochemistry, 1996, 35(36):11529-11535.
25 Siprashvili Z,Sozzi G,Barnes LD,et al.Replacement of FHIT in cancer cells suppresses tumorigenicity.Proc Natl Acad Sci USA,1997,94(25):13771-13776.
26 Sard L,Accornero P,Tornielli S,et al.The tumor suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control.Proc Natl Acad Sci USA, 1999, 96(15): 8489-8492.
27 Ji L,Fang B,Yen N,et al.Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.Cancer Res,1999,59(14)B3333-3339.
28 Lima CD,D.Amico KL,Naday I,et al.MAD analysis of FHIT,a putative human tumor suppressor from the HIT protein family.Structure,1997,5(6):763-774.
29 Brenner C.FHIT-substrate complexes:a new paradigm in reversible protein phosphoryla-tion. Phosphorous,Sulfur,and Silicon,1998,144-146:746-752.
30 Brenner C,Bieganowski P,Pace HC,et al.The histidine triad superfamily of nucleotidebind-ing proteins.J Cell Physiol,1999,181(2):179-187.
31 Kuroki T,Trapasso F,Yendamuri S,et, al.Allele loss and promoter hypermethylation of VHL,RAR,beta,RASSFIA,and FHIT tumor suppressor genes on chromosome 3p in esophageal squanmous cell carcinoma.Cancer Res,2003,63(13):3724-3728.
32 [Maruyama R,Toyooka KO,et,al.Aberrant promoter methylation profile of bladdercancer and its relationship to clinicopthological features J].Cancer Res,2001,61 (24):8659.
33 Zochbauer Muller S,Fong KM,Maitra A,et,al.5CPG island methylation of the FHITgene is correlated with loss of gene expression in lung and breast cancer.Cancer Res,2001,61(9):3581-3585.
34 Wada T,Louhelainen J,Hemminki K,et al.The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction [J].BJU Int,2001,87:876-881.
35 Raffaele B,leconardG,Gomella,et al.Loss of FHIT expression intransitional cell carcinoma of the urinary bladder [J].Am J Pathol,2000,156:419-424.
36何崇生,黄剑飞,陈莉.脆性组胺酸三聚体基因(FHIT)在膀胱移行细胞肿瘤的表达及其临床意义[J].苏州大学学报,2006,26(2):265-266
1 Holcik M.The IAP proteins[J].Trends in genetics,2002,18(10):537-538.
2 Ambrosini G,Adida C,Altieri DC. A novel anti-apoptosis gene,surviving, expressed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921.
3 Chantalat L,Skoufias DA,Kleman JP,et al.Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions[J].Mol Cell,2000,6(1): 183-189.
4 O' Connor DS,Grossman D,Plescia J, et al.Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin[J]. Proc Natl Acad Sci USA, 2000, 97(24):13103- 13107.
5 Tamm I,Wang Y,Sausville E,et al.IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bas,caspase,and anticancer drugs[J].Cancer Res,1998,58(23): 5315-5320.
6 Sela B.Survivin:Anti-apoptosis protein and a prognosticmarker for tumor progression and recurrence[J].Harefuah, 2002,141(1):103-107.
7 Lehner R,Lucia MS,Jarboe EA,et al.Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma[J].Appl Immunohistochem MolMorphol, 2002,10 (2):134-138.
8 Mahotka C,Wenzel M,Springer E,et al.Survivin-delta Ex3 and surviving-2B:two novel splice variants of the apoptosis inhibitor surviving with different antiapoptotic properties[J].Cancer Res,1999,59(24):6097-6102.
9 Krieg A,Mahotka C,Krieg T, et al.Expression of different survivin variants in gastric carcinomas: first clues to a role of surviving-2B in tumour progression[J].BrJ Cancer,2002,86(5):737-743.
10 Vegran F,Boidot R,Oudin C,et al.Distinct expression of surviving splice variants in breast carcinomas[J].Int J Oncol,2005,27(4):1151-1157.
11 Zheng W,Ma X,Wei D,et al.Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells[J].DNA Seq, 2005, 16(5):321-328.
12 Dohi T,Okada K,Xia F,et al.An IAP-IAP complex inhibits apoptosis[J].J Biol Chem 2004; 279(33): 34087-34090.
13 Tamm I, Wang Y, Sausville E,et al.IAP-family protein surviving inhibits caspases, and anticancer drugs[J].Cancer Res,1998,58: 5315-5320.
14 Verhagen AM,Ekort PG,Pakusch M,et al.Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins[J]. Cell,2000, 102(1):43-53.
15 Mitza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-depend apoptotic pathway[J].Oncogene, 2002,21(17):2613-2622.
16 Fortugno P,Wall NR,Giodini A,et al.Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function[J].J Cell Sci,2002,115 (3):575-585.
17 Takai N,Miyazaki T,Nishida M,et al.Survivin expression correlates with clinical stage, histologicalgrade, invasive behaviorand survival rate in endometrial carcinoma[J]. Cancer Lett,2002,184(1):105-106.
18 Thompson CB.Apoptosis in the pathogenesis and treatment of disease [J]. Science, 1995, 267 (5203):1456-1462.
19 Smith SD, Wheeler MA, Plescia, et al.Urine detection ofSurvivin and diagnosis ofbladder cancer[J]. JAMA, 2001, 285(3): 324-328.
20 Sharp JD,HausladenDA,MaherM G,et al.Bladder cancerdetection with urinary survivin, an Inhibitor ofapoptosis[J].FrontBiosci,2002,7: 36-41.
21 Shariat SF,Casella R,Khoddami SM,et al.Urine survivin detection is a sensitivemarker for the noninvasive diagnosis of bladder cancer[J].J Urol, 2004, 171(2 pt1):626-630.
22 Ku JH,Kwak C,Lee HS,et al.Expression of survivin, a noval inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder[J].J Urol, 2004,171(2 pt1): 631-635.
23 Hausladen DA,Wheeler MA,Altieri DC,et al.Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome[J].J uro,2003,170(1):230-234.
24 Xing Z,Conway EM.Essential role of surviving,an inhibitor of apoptosis protein, in T cell development ,maturation, and homeostasis [J].J Exp Med,2004,199(1):69-80.
25 Hu Y,Cherton-Horvat G,Dragowska V,et al.Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo [J].Clin Cancer Res,2003,9:2826-2836.
26 Tu SP,Jiang XH,Lin MC,et al.Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer [J]. Cancer Res,2003,63:7724.7732.
27 Hague A, Eveson JW, MacFarlane M,et al.Caspase-3 expression is reduced in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage[J]. J Pathol,2004, 204:175-182.
28 Zhang XY, Zhong LH,Hu K,et al.Expression of survivin and its correlation with P53 in non-small cell lung cancer[J].Med J Wuhan University,2004,25(3):271-274.
29 Meng H,Lu C,Mabuchi H,et al.Prognostic significance and different properties of survivin splicing variants in gastric cancer[J].Cancer Lett,2004,216:147-155.
30 Olie RA,Simoes-Wust AP,Baumann B,et al.A novel antisense oligonucleotide targeting Surviving expression induces apoptosis and sensitizes lung cancer cells to chemotherapy [J].CancerRes,2000, 60(1): 2805-2809.
31 Kato J,Kuwaabara Y,MitaniM,et al.Expression of survivin in esophageal cancer correlation with the prognosis and response to chemotherapy[J]. Int JCancer, 2001, 95(2):92-95.
32 Mesri M,WallN R,Li J,et al.Cancer gene therapy using a surviving mutant adenovirus [J].J Clin Invest, 2001, 108(7):981-990.
33 Gazzaniga P,Gradilone A,Giuliani L,et al.Expression and prognostic significance of livin, Surviving and other apoptosis-related genes in the progression of superficialbladder cancer[J].AnnOnco,l 2003,14(1):85-90.
34 Mesri M,Morales-Ruiz M,Ackermann EJ,et al.Suppression of vascular endothelial growthfactor-mediated endothelial cell proteition by Survivin targeting[J].AmJ Pathol,2001,8(4):305-310.